without affecting the antiarrhythmic properties of disopyramide , a sustained-release form of pyridostigmine ( a cholinesterase inhibitor ) was shown to prevent completely anticholinergic side effects in a study population ( 17 patients ) , whereas side effects occurred in 26 of 89 patients ( 29 % ) in a control group ( p less than 0.025 ) .
C0003195
antiarrhythmic
C0012702
disopyramide